key: cord-0883831-i2hcetvo
authors: Shu, Bo; Kirby, Marie K.; Davis, William G.; Warnes, Christine; Liddell, Jimma; Liu, Ji; Wu, Kai-Hui; Hassell, Norman; Benitez, Alvaro J.; Wilson, Malania M.; Keller, Matthew W.; Rambo-Martin, Benjamin L.; Camara, Yamundow; Winter, Jörn; Kondor, Rebecca J.; Zhou, Bin; Spies, Stacey; Rose, Laura E.; Winchell, Jonas M.; Limbago, Brandi M.; Wentworth, David E.; Barnes, John R.
title: Multiplex Real-Time Reverse Transcription PCR for Influenza A Virus, Influenza B Virus, and Severe Acute Respiratory Syndrome Coronavirus 2
date: 2021-07-03
journal: Emerg Infect Dis
DOI: 10.3201/eid2707.210462
sha: 47776f8bca6d3b2d71150017809e67dbd0b240ec
doc_id: 883831
cord_uid: i2hcetvo

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019, and the outbreak rapidly evolved into the current coronavirus disease pandemic. SARS-CoV-2 is a respiratory virus that causes symptoms similar to those caused by influenza A and B viruses. On July 2, 2020, the US Food and Drug Administration granted emergency use authorization for in vitro diagnostic use of the Influenza SARS-CoV-2 Multiplex Assay. This assay detects influenza A virus at 10(2.0), influenza B virus at 10(2.2), and SARS-CoV-2 at 10(0.3) 50% tissue culture or egg infectious dose, or as few as 5 RNA copies/reaction. The simultaneous detection and differentiation of these 3 major pathogens increases overall testing capacity, conserves resources, identifies co-infections, and enables efficient surveillance of influenza viruses and SARS-CoV-2.

critical guidance on selection of candidate vaccine strains; these processes also identify antiviral resistance genes and novel influenza viruses that have pandemic potential (8) .

We evaluated existing and novel SARS-CoV-2 primers and probes to identify the optimal SC2 assay components for this quadruplex rRT-PCR (Appendix Table 1 , https://wwwnc.cdc.gov/EID/ article/27/7/21-0462-App1.pdf). The SC2 assay components are selective for the 3′ region of the SARS-CoV-2 genome from the carboxy terminus of the nucleocapsid (N) gene into the 3′ untranslated region (UTR). The primer and probe sequences for the influenza A (InfA), influenza B (InfB), and RP targets are identical to those used in the singleplex assays of the US Food and Drug Administration (FDA)-approved CDC Human Influenza Virus Real-Time RT-PCR Detection and Characterization Panel [510(k) no. K200370] (9) . The Flu SC2 Multiplex Assay is selective for the matrix (M) gene segment of the influenza A virus, the nonstructural (NS) gene segment of the influenza B virus, and the human ribonuclease P/MRP subunit P30 gene; the InfA assay is designed for universal detection of all influenza A viruses and InfB assay is designed for universal detection of all influenza B viruses (10) (11) (12) (13) (14) . The InfA assay was recently updated to address evolutionary changes and reactivity challenges; the updated CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel was cleared by FDA in 2020 (9) . On July 2, 2020, FDA granted an emergency use authorization (EUA) for in vitro diagnostic use of the Flu SC2 Multiplex Assay (15) .

Multiplex detection of RNA from influenza A virus, influenza B virus, and SARS-CoV-2 can increase testing capacity and reduce use of reagents. The increased throughput can preserve staff resources and reduce turnaround time. The Flu SC2 Multiplex Assay and similar panels identify co-infections or alternative causes of influenza-like and COVID-19-like illnesses. The Flu SC2 Multiplex Assay can enable collection of critical data on influenza A and B viruses and SARS-CoV-2, as well as the prevalence of co-infection among these respiratory viruses.

Influenza viruses were grown to high titer in Madin-Darby Canine Kidney cells or embryonated chicken eggs. Infectious virus titer in the cell culture supernatant or allantoic fluid was measured by using 50% tissue culture infectious dose (TCID 50 ) or 50% egg infectious dose (EID 50 ) (16) . The SARS-CoV-2 virus (2019-nCoV/USA-WA1/2020; GenBank accession no. MT576563) was grown to high titer in Vero cells; the infectious virus titer in the cell culture supernatant was measured by using TCID 50 (16) . Total nucleic acids were extracted by using the EZ1 DSP Virus Kit on the EZ1 Advanced XL automated extractor (QIA-GEN, https://www.qiagen.com).

Primers and probes were selected from highly conserved regions of the SARS-CoV-2 genome based on ≈4,000 sequences available in GISAID (https://www. gisaid.org) in March 2020 (Table 1 ). Primer Express 3.0.1 software (Thermo Fisher Scientific, https:// www.thermofisher.com) was used to design primers that had annealing temperatures of ≈60°C and probes that had annealing temperatures of ≈68°C.

The multiplex assay probes were synthesized by using ZEN or TAO Double-Quenched Probes labeled at the 5′ end using reporter 6-carboxyfluorescein (FAM) for InfA, Yakima Yellow for InfB, Texas Red-XN for SARS-CoV-2, and Cyanine 5 (Cy 5) for RP targets (Integrated DNA Technologies, Inc., https://www.idtdna.com). The InfA and InfB probes were quenched with ZEN between nucleotides 9 and 10 and with Iowa Black FQ at the 3′ end; the SARS-CoV-2 and RP probes were quenched with TAO between nucleotides 9 and 10 and with Iowa Black RQ at the 3′ end (Integrated DNA Technologies, Inc.). Primers and Taqman hydrolysis probes were synthesized by Integrated DNA Technologies and the CDC Biotechnology Core Facility Branch (Division of Scientific Resources, National Center for Emerging and Zoonotic Infectious Diseases; Atlanta, Georgia, USA).

The rRT-PCR reactions of the Flu SC2 Multiplex Assay were optimized and conducted by using the Taq (9, 17) . We used the following thermocycling conditions for RT-PCR for Influenza Viruses and SARS-CoV-2 rRT-PCR: 25°C for 2 min, 50°C for 15 min, Taq activation at 95°C for 2 min, 45 cycles at 95°C for 15 sec, and 55°C for 30 sec. We conducted comparator reactions using influenza singleplex rRT-PCR and the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel, as described previously (7, 10, 17) .

A quantified synthetic RNA material (Armored RNA Quant CDC-9; Asuragen, Inc., https://asuragen.com) was used to test analytical sensitivity. The synthetic RNA included primer-probe region sequences derived from the M gene of A/Brisbane/02/2018_(H1N1)pdm09 (GISAID accession no. EPI1799928), for the InfA target, the NS gene of B/Colorado/06/2017_Victoria (GISAID accession no. EPI1056634) for the InfB target, and the Homo sapiens (human) ribonuclease P/MRP subunit P30 gene for the RP target. We used RNA extracted from propagated, A/Illinois/20/2018_(H1N1)pdm09 (GI-SAID accession no. EPI1220313; GenBank accession no. MH359945), and B/Colorado/06/2017_Victoria viruses to test the analytical sensitivity of the InfA and InfB targets. We used Twist Synthetic SARS-CoV-2 RNA Control 2 (Twist Bioscience, https:// www.twistbioscience.com) and RNA extracted from propagated SARS-CoV-2 virus (2019-nCoV/USA-WA1/2020) to assess analytical sensitivity of the SARS-CoV-2 target.

We evaluated assay specificity by using a panel of influenza A virus, influenza B virus, and SARS-CoV-2. This panel included influenza A(H1/H3) variant viruses that usually circulate among swine and have caused outbreaks and pandemics in human populations (18) (19) (20) (21) (22) .

We used a collection of influenza C viruses, coronaviruses, and human noninfluenza respiratory pathogens to test the analytical specificity of the Flu SC2 Multiplex Assay. We also tested the specificity of the SARS-CoV-2 target with an RNA transcript generated from a clone representing nt 27768-29738 of the severe acute respiratory syndrome coronavirus (SARS-CoV)/Urbani genome, which contains the entire N gene through the 3′-terminus, and a full SARS-CoV viral genome.

To test sensitivity to co-infection, we created a serial dilution with nucleic acids extracted from A/Illinois/20/2018_(H1N1)pdm09, B/Colorado/06/2017_ Victoria, 2019-nCoV/USA-WA1/2020, and adenocarcinomic human alveolar basal epithelial cells (A549). We tested the dilution by the Flu SC2 Multiplex Assay, influenza A and influenza B singleplex rRT-PCR from the CDC rRT-PCR Flu Dx Panel Influenza A/B Typing Kit, and the N1 component of the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel.

We tested the specificity and sensitivity of each primer and probe oligonucleotide sequence for the SARS-CoV-2 target of the Flu SC2 Multiplex Assay by BLAST analysis (http://blast.ncbi.nlm.nih.gov/ blast.cgi) against the nr/nt database and the National Center for Biotechnology Iinformation and GISAID β Coronaviridae nucleotide database. We analyzed results and assessed for potential non-SARS-CoV-2 matches (Appendix). We compared the primer and probe sequences with SARS-CoV-2 variant sequences available in GISAID on January 19, 2021, including 501Y.V1, a B.1.1.7 variant from the United Kingdom; 501Y.V2, a B.1.351 variant from South Africa; and 501Y.V3, a P.1 variant from Brazil.

We evaluated the clinical performance of the Flu SC2 Multiplex Assay using 104 upper and lower respiratory specimens, including oral swab, throat swab, nasopharyngeal swab, oropharyngeal swab, and sputum samples. Total nucleic acids were extracted from 120 µL of each clinical specimen by using the EZ1 DSP Virus Kit on the EZ1 Advanced XL automated extractor (QIAGEN). The extracted material was eluted in 120 µL elution buffer. Specimens were tested with the Flu SC2 Multiplex Assay, the CDC Human Influenza Real-Time RT-PCR Diagnostic Panel: Influenza A/B Typing Kit version 2 [510 (k) no. K200370], or the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel, as described previously (7, 9) .

We identified candidate SARS-CoV-2 targets and evaluated them by an in silico screening process. This process identified targets with very few mismatches across the available SARS-CoV-2 genomes and accounted for RNA structural elements known to be essential for related betacoronaviruses. In total, we tested 17 SARS-CoV-2 assay designs in singleplex format; we subsequently tested a subset of these candidates using the multiplex format, including published targets in the RNA-dependent RNA polymerase and E gene regions (Appendix Table 1 ) (23) . We selected for the assay the SARS-CoV-2 target with the highest levels of sensitivity and specificity and that accurately identified residual clinical respiratory specimens.

The SARS-CoV-2 assay is selective for the 3′ region of the SARS-CoV-2 genome from the carboxy terminus of the of the N gene into the 3′-UTR (Appendix Figure) . This region is expressed at high levels in infected cells and is highly conserved because it encodes a cis-acting RNA pseudoknot essential for the transcription and replication of closely related betacoronaviruses (24) .

We determined the analytical sensitivity of the Flu SC2 Multiplex Assay by calculating the limits of detection using extracted RNA from influenza A virus, influenza B virus, and SARS-CoV-2. We used serial 10-fold dilutions of extracted RNA to identify an endpoint for detection with each primer and probe set included in the multiplex assay (data not shown). After a detection range was established, we tested Table 2) . We determined the limits of detection to be 10 2.0 TCID 50 for influenza A, 10 2.2 EID 50 for influenza B, and 10 0.3 TCID 50 for SARS-CoV-2 (Table 2) . These values correspond to 10 -0.3 TCID 50 for each influenza A reaction, 10 -0.1 EID 50 for influenza B, and 10 -2.0 TCID 50 for SARS-CoV-2 (i.e., 5 µl RNA/reaction). We confirmed the LOD through further testing of 20 replicate viral isolates mixed with A549 cells at the established LOD and at a 5-fold dilution step above the established LOD; this process demonstrated that the multiplex assay can detect >95% of samples at the lowest detectable concentrations (Table 3; Appendix Table 2 ). The SD across the 20-replicate experiment was very low, demonstrating the consistency of the multiplex results even at the LOD (Table 3) .

We used an engineered RNA construct (Armored RNA Quant CDC-9; Asuragen, Inc.) containing the target sequences for the InfA, InfB, and RP assays to test the copy number sensitivity of the multiplex assay through serial dilutions. We assessed copy number sensitivity of the SARS-CoV-2 assay by using a serial dilution of a synthetic SARS-CoV-2 genome (GenBank accession no. MN908947.3; Twist Bioscience). All targets in the assay could detect as few as 5 RNA copies per reaction (Table 4 ).

Initially, the Flu SC2 Multiplex Assay was screened using no template control reactions; we found no intramolecular or intermolecular nonspecific interactions that resulted in any products (data not shown). The specificity of the primers and probes was evaluated with viral RNA from 13 influenza A, 2 influenza B, and 1 SARS-CoV-2 isolate. The viral RNAs were tested at high and low titers; each assay accurately detected the corresponding viral target (Table 5) . We observed no cross-reactivity among the 4 targets within the assays, nor did we observe any bleed-through fluorescence imaging from neighboring channels when testing the individual assays (Table 5) .

To confirm that the SARS-CoV-2 assay was specific to that virus, we tested 6 known human coronaviruses, 2 alphacoronaviruses, 2 group A betacoronaviruses, and 2 group B betacoronavirus (i.e., SARS-CoV and Middle East respiratory syndrome coronavirus [MERS-CoV]), as well as an RNA transcript including the entire SARS-CoV N gene region through the 3′ UTR. No cross-reactivity was observed, demonstrating the high specificity of the assay (Appendix Table 3 ). To further evaluate the specificity of the multiplex assay, we also tested common respiratory pathogens and genetic near neighbors of viruses selected for by the assay. Nucleic acids from high titer viral preparations were extracted and tested with the Flu SC2 Multiplex Assay; no cross-reactivity was observed (Appendix Table 4 ).

An extensive in silico BLAST analysis of the primer and probe sequences for the SARS-CoV-2 target confirmed that the assay is specific to SARS-CoV-2; no evidence of non-SARS-CoV-2 target matches was found ( Figure; Appendix Table 5 ). These results demonstrate that Flu SC2 Multiplex Assay is specific to get. This analysis demonstrated that during January 2021, most (>99.5%) of the variant virus sequencing data was identical to the SARS-CoV-2 target sequence; of the genomes that had <100% match, none except 2 sequences displayed >1 mismatch for any region of the assay (Appendix Table  6 ). Therefore, the Flu SC2 Multiplex Assay should accurately detect the B.1.1.7, B.1.351, and P.1 SARS-CoV-2 variants.

We evaluated the analytical sensitivity of the multiplex assay in the context of a mock co-infection scenario by testing a mixture of nucleic acids extracted from influenza A, influenza B, SARS-CoV-2, and A549 cells with the Flu SC2 Multiplex Assay and the InfA, InfB, and N1 singleplex assays (7, 9) . The results demonstrated that the multiplex assay can detect all 4 targets simultaneously at comparable or higher sensitivity levels than each singleplex comparator (Appendix Table 7 ).

We evaluated the clinical performance of the multiplex assay by using residual clinical respiratory specimens. Nucleic acids were extracted from 104 prospective and retrospective clinical specimens, including 33 SARS-CoV-2-positive, 30 influenza Apositive, 30 influenza B-positive, and 11 negative residual clinical samples. The samples were tested with the Flu SC2 Multiplex Assay; the results were in 100% agreement with the expected value for each specimen ( Table 6; Appendix Tables 8, 9 ).

SARS-CoV-2 emerged in December 2019 and quickly spread, causing the COVID-19 pandemic. As the SARS-CoV-2 infection rate increased, the demand for viral diagnostic testing also increased. The Flu SC2 Multiplex Assay increases throughput and uses less reagent than the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel, thus improving SARS-CoV-2 testing efficiency. The multiplex assay enables laboratories to simultaneously test for influenza viruses and SARS-CoV-2, an application that is especially useful because influenza virus and SARS-CoV-2 infections cause similar signs and symptoms (25, 26) . Although not described in this article, additional enzyme master mix combinations, nucleic acid extraction platforms, and an alternative manufacturer were added to the assay EUA, further improving its utility (15, 27) . CDC granted the right of reference to all data submitted to the FDA for EUA authorization of the Flu SC2 Multiplex Assay. Several commercial providers have leveraged the data to produce multiplex kits, including the BioSearch Valuepanel (LGC BioSearch Technologies, https://www.biosearchtech.com), PrimeTime The analytical sensitivity of the Flu SC2 Multiplex Assay was evaluated; each component was comparable to the singleplex versions of each assay. The assay detects titers as low as 10 2.2 -10 0.3 TCID 50 or EID 50 (or 10 -2.0 -10 −0.1 TCID 50 or EID 50 /reaction) of influenza A viruses, influenza B viruses, and SARS-CoV-2, or as few as 5 RNA copies/reaction. We observed no cross-reactivity among the targets, even at high viral titers; none with the other 6 known human coronaviruses, including SARS-CoV and MERS-CoV; and none with influenza C cultured viruses or other common noninfluenza respiratory pathogens (28) . The Flu SC2 assays manufactured by CDC are evaluated to ensure that the LOD of each lot is comparable with the LOD established in the EUA. Quality assessments ensure limited variability: lots that have a variance of >2 cycle thresholds from the EUA submission data against standard quality control virus dilution series are deemed unacceptable for distribution (data not shown). These standards ensure that sensitivity and specificity are maintained through the manufacturing process.

The SARS-CoV-2 target used by the multiplex panel was selected from a conserved and vital region of the N gene (29) . Analytical evaluation and in silico analysis demonstrated the target is sensitive and specific to SARS-CoV-2 and will not detect other human coronaviruses, including SARS-CoV and MERS-CoV. The in silico analysis of 376,469 SARS-CoV-2 sequences available in GISAID in January 2021 indicated that >99.9% of the viruses have <1 mismatch within a single primer or probe of the SARS-CoV-2 assay (Appendix Table 5 ). An in silico analysis of genomes from the emerging SARS-CoV-2 B.1.1.7, B.1.351, and P.1 variants demonstrated that the target is identical to the genome sequence for >99.5% of these variant genomes (Appendix Table 6 ). The Flu SC2 Multiplex Assay should detect these emerging variants because the mutations associated with these variants are located within a different region of the genome than the target.

The Flu SC2 Multiplex Assay was evaluated using a reference panel developed by the FDA for assessing diagnostic nucleic acid amplification tests for SARS-CoV-2 (30, 31) . The panel consisted of reference SARS-CoV-2 material, blinded samples, and a protocol provided by the FDA. The evaluation included range finding and confirmatory studies for LOD, as well as blinded sample testing to establish specificity and further confirmation of the LODs. The LOD of the Flu SC2 Multiplex Assay using the FDA panel was 5.7 × 10 3 nucleic acid amplification test detectable units/mL, with no observable crossreactivity with MERS-CoV (32) .

In summary, the Flu SC2 Multiplex Assay demonstrates a high level of specificity and sensitivity. In a single reaction, it can detect and distinguish 3 major respiratory viruses as well as the human quality control target, thereby increasing the testing throughput. Additional advantages of the Flu SC2 Multiplex Assay include fewer freeze-thaw cycles, decreased potential for contamination through a reduction in the number of reactions, and fewer opportunities for pipetting errors. With this multiplex assay, users can rapidly test large amounts of samples. Although the influenza season for 2020-21 had historically few cases, this assay will be beneficial in upcoming influenza seasons when influenza might co-circulate with SARS-CoV-2.

World Health Organization. Pneumonia of unknown cause-China

China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China

WHO declares COVID-19 a pandemic

An interactive web-based dashboard to track COVID-19 in real time

FDA chief warns of supply pressure on reagents for coronavirus tests. MedTech Dive

It's like Groundhog Day: coronavirus testing labs again lack key supplies. The New York Times

US CDC real-time reverse transcription PCR panel for detection of severe acute respiratory syndrome coronavirus 2

Influenza vaccines: challenges and solutions

US Food and Drug Administration. 510 (k): CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel. 2020

Human Influenza Virus Real-Time RT-PCR Detection and Characterization Panel: 510(k) 080570

World Health Organization. CDC protocol of realtime RT-PCR for influenza H1N1

World Health Organization. Real-time RT-PCR protocol for the detection of avian influenza A(H7N9) virus

New traditional 510(k): CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel

Detection and discrimination of influenza B Victoria lineage deletion variant viruses by real-time RT-PCR

Coronavirus (COVID-19) update: FDA authorizes additional COVID-19 combination diagnostic test ahead of flu season

Influenza: propagation, quantification, and storage

Design and performance of the CDC real-time reverse transcriptase PCR swine flu panel for detection of 2009 A (H1N1) pandemic influenza virus

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans

Outbreak of variant influenza A(H3N2) virus in the United States

Global transmission of influenza viruses from humans to swine

Adaptation of human influenza viruses to swine

Outbreak of influenza A(H3N2) variant virus infections among persons attending agricultural fairs housing infected swine-Michigan and Ohio

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Genetic interactions between an essential 3′ cis-acting RNA pseudoknot, replicase gene products, and the extreme 3′ end of the mouse coronavirus genome

Co-infection with influenza A and COVID-19

A case series of patients coinfected with influenza and COVID-19

Coronavirus disease 2019 (COVID-19) emergency use authorizations for medical devices: in vitro diagnostics EUAs

Isolation, propagation, genome analysis and epidemiology of HKU1 betacoronaviruses

RNA genome conservation and secondary structure in SARS-CoV-2 and SARS-related viruses: a first look

FDA sets up SARS-CoV-2 reference panel for diagnostic tests

Coronavirus (CO-VID-19) update: FDA provides new tool to aid development and evaluation of diagnostic tests that detect SARS-CoV-2 infection

SARS-CoV-2 reference panel comparative data

We acknowledge and thank the Laboratory and Testing Task